Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NKTR
- Price
- 36.53
- Stock movement down
- -0.39 (-1.06%)
- Company name
- Nektar Therapeutics
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 743.08M
- Ent value
- 918.31M
- Price/Sales
- 11.87
- Price/Book
- 8.73
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 28.07%
- 1 year return (CAGR)
- 3940.93%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NKTR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.87 |
| Price to Book | 8.73 |
| EV to Sales | 14.67 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 20.34M |
| EPS (TTM) | -8.57 |
| FCF per share (TTM) | -13.51 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 62.60M |
| Gross profit (TTM) | 54.62M |
| Operating income (TTM) | -98.09M |
| Net income (TTM) | -120.74M |
| EPS (TTM) | -8.57 |
| EPS (1y forward) | -11.86 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.26% |
| Operating margin (TTM) | -156.69% |
| Profit margin (TTM) | -192.87% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 41.03M |
| Net receivables | 1.29M |
| Total current assets | 281.36M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 10.00M |
| Total assets | 301.35M |
| Accounts payable | 15.56M |
| Short/Current long term debt | 91.92M |
| Total current liabilities | 66.34M |
| Total liabilities | 216.26M |
| Shareholder's equity | 85.09M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -189.74M |
| Capital expenditures (TTM) | 612.00K |
| Free cash flow (TTM) | -190.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -141.90% |
| Return on Assets | -40.07% |
| Return on Invested Capital | -112.55% |
| Cash Return on Invested Capital | -177.45% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 36.92 |
| Daily high | 37.99 |
| Daily low | 35.77 |
| Daily Volume | 600K |
| All-time high | 108.44 |
| 1y analyst estimate | 114.43 |
| Beta | 1.28 |
| EPS (TTM) | -8.57 |
| Dividend per share | 0.00 |
| Ex-div date | 11 Jun 2014 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NKTR | S&P500 | |
| Current price drop from All-time high | -66.31% | -0.89% |
| Highest price drop | -99.55% | -19.00% |
| Date of highest drop | 7 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -80.87% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
743.08M
Marketcap category
Small-cap
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Employees
61
Website
Investor relations
-
SEC filings
CEO
Howard W. Robin
Country
USA
City
San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page